Dong A St Co., Ltd - Sep 18, 2024 Form 4 Insider Report for NeuroBo Pharmaceuticals, Inc. (NRBO)

Role
10%+ Owner
Signature
Dong-A St Co., Ltd.; By: /s/ Jae Hun Jung, Chief Executive Officer
Stock symbol
NRBO
Transactions as of
Sep 18, 2024
Transactions value $
-$1,526
Form type
4
Date filed
9/20/2024, 04:20 PM
Previous filing
Jul 10, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NRBO Common Stock Sale -$1.53K -407 -0.01% $3.75 5.35M Sep 12, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRBO Warrants to Purchase Common Stock Purchase +2.54M 2.54M Sep 18, 2024 Common Stock 2.54M $3.93 Direct F2, F3
transaction NRBO Warrants to Purchase Common Stock Purchase +3.82M 3.82M Sep 18, 2024 Common Stock 3.82M $3.93 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reporting Person's sale of 407 shares of Common Stock at a price per share of $3.75 occurred on September 12, 2024.
F2 On June 13, 2024, the Issuer issued (i) Series A Warrants to purchase up to an aggregate of 2,544,530 shares of the Issuer's common stock (the "Series A Warrant Shares") and (ii) 3,816,795 Series B Warrants to purchase up to an aggregate of 3,816,795 shares of the Issuer's common stock (the "Series B Warrants", and collectively with the Series A Warrants, the "Warrants"), to the reporting person pursuant to a securities purchase agreement dated the same date (the "Purchase Agreement"), in connection with a private placement of securities by the Issuer to certain investors. The issuance of the Warrants under the Purchase Agreement was subject to stockholder approval under applicable NASDAQ rules, which was obtained at a special meeting of the Issuer's stockholders held on September 18, 2024.
F3 These warrants expire on the earlier of (i) the twelve months anniversary of September 18, 2024, and (ii) the 60th day following the date on which the Issuer publicly announce the receiving of positive Phase 1 MAD data readout for DA-1726.
F4 These warrants expire on the earlier of (i) the five years anniversary of September 18, 2024 and (ii) the six months anniversary following the date on which the Issuer publicly announce the receiving of positive Phase 1, Part 3 data readout for DA-1726.